New pill targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 partic…
Phase: PHASE1 • Sponsor: Nested Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC